Filing Details
- Accession Number:
- 0001181431-14-001309
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-01-06 16:30:27
- Reporting Period:
- 2014-01-02
- Filing Date:
- 2014-01-06
- Accepted Time:
- 2014-01-06 16:30:27
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1113148 | Infinity Pharmaceuticals Inc. | INFI | Pharmaceutical Preparations (2834) | 330655706 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1492805 | J. Vito Palombella | C/O Infinity Pharmaceuticals, Inc. 780 Memorial Drive Cambridge MA 02139 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-12-31 | 753 | $11.74 | 753 | No | 5 | A | Direct | |
Common Stock | Disposition | 2014-01-02 | 753 | $13.52 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 5 | A | Direct | |
No | 4 | S | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 5,923 | Indirect | By 401k |
Footnotes
- The acquisition represents shares purchased through participation in the issuer's Employee Stock Purchase Plan in a transaction exempt under both Rule 16b-3(c) and Rule 16b-3(d).
- The disposition reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2013.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.38 to $13.63, inclusive. The reporting person undertakes to provide to Infinity Pharmaceuticals, Inc., any security holder of Infinity Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3.